Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Blocking a specific protein improves CAR T-cell therapy success in patients with blood cancers

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers. In a recent study published in Signal Trans

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

In a recent study published in Signal Transduction and Targeted Therapy, scientists found increased survival and tumor-fighting activity in lab and animal models when they blocked a specific protein in the modified cells.

CAR T-cell therapy involves genetically engineering a patient's T-cells, or immune cells, to attack cancer cells and then infusing those cells back into the patient. The therapy can be remarkably effective, but most patients still experience a relapse within 5 years of treatment.

Genetically engineered cells are a promising new way to treat cancer and autoimmune diseases. However, scientists are still figuring out how these cells work and how to make them better." Tim Luetkens, MD, Associate Professor of Microbiology and Immunology at UMSOM and senior author of the study

Kenneth Dietze, PhD, first author of this study and a research fellow in the Luetkens lab at UMSOM, discovered that some CAR T-cells tear off tiny pieces from the surface of cancer cells and put those pieces onto themselves. "This process makes the CAR T-cells less effective at attacking cancer," said Dr. Luetkens, who is also Director of Research and Development at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) Fannie Angelos Cellular Therapeutics GMP Lab.

This is a lattice light sheet microscopy image of a CAR T cell (purple cell in the middle), ripping fragments off the surrounding tumor cells (green cells). The image was created by Kiet Nguyen, Elizabeth Anne Kiely, and Dr. Arpita Upadhyaya.

The study team discovered that blocking a protein called cathepsin b prevented the tearing process in CAR T-cells and allowed them to stay active longer, therefore making them better at fighting cancer.

"I am proud of UMGCCC's continued innovation in CAR T-therapy," said Taofeek K. Owonikoko, MD, PhD, Executive Director of UMGCCC and the Kevin Cullen Distinguished Professor in Oncology at UMSOM. "While these findings need to be translated into human clinical trials, this is real progress that could ultimately improve durability and outcomes for our patients."

UMGCCC researchers are also leading an ongoing first-in-human clinical trial using CAR T-cell therapy in patients with recurrent or difficult-to-treat B-cell lymphoma.

This research was done together with the Upadhyaya lab at the University of Maryland, College Park, where the team used advanced imaging techniques to directly watch how CAR T-cells tear off fragments from cancer cells.

This work was supported through the Maryland Department of Health's Cigarette Restitution Fund Program (CH-649-CRF), the National Cancer Institute Cancer Center Support Grant (P30CA134274), the National Cancer Institute of the National Institutes of Health (1R21CA297125), the National Institutes of Health (R35 GM145313), an NIAID-funded predoctoral fellowship (T32 AI095190), and the American Cancer Society (DBG-25-1434942-01-ET)."

Dietze, K. A., et al. (2026). Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function. Signal Transduction and Targeted Therapy. DOI: 10.1038/s41392-026-02654-z. https://www.nature.com/articles/s41392-026-02654-z

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What’s your vision for BenevolentBio?

I want us to disrupt the drug discovery and development process and to look at each place on the drug discovery and development pipeline, so that we can be much better at getting the right target, much quicker at getting the right compound and much more confident that those compounds have the right characteristics which mean they will be safe and well tolerated. Then we can go to the right patient population with the right dose, so we would have a much leaner, more successful process and be able to demonstrate the value of our AI technology.

Source: www.news-medical.net ↗
02What are the Advantages of Affimers?

Affimers are small in size, stable at different temperature ranges, relatively easy to generate, and offer appealing opportunities to complement the shortcomings of antibodies. Their small size is thought to be one of the attributes making affimers more sensitive than antibodies when used in histochemical staining, as they can penetrate tissues better. Affimers are both commercially available and can be synthesized by individual laboratories using publicly available methods, thereby ensuring it is accessible to the entire scientific community. One key advantage of affimers, as opposed to antibodies or nanobodies, is the speed at which they can be screened and developed. The screening process for affimers involves three iterations of phage display and ELISA assays. This can be carried out in 12 days, which is significantly less than the time needed for antibody and nanobody animal inoculation times. Furthermore, the screening process by which binding reagents are identified is more efficient because the target proteins are screened in a folded state.

Source: www.news-medical.net ↗
03What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
04Collaboration has played a significant role in your research career. Can you highlight some of the most impactful collaborations you've had and how they have contributed to your research in axon biology?

A significant collaboration is with the Versus Arthritis Pain Center in Nottingham, in particular with Vicky Chapman and Gareth Hathway. Initially, my work wasn't focused on pain research, but joining forces with experts from this center led half of my lab's work to be directed towards pain-related projects. Another meaningful collaboration involves studying motor neuron diseases alongside Prof. Rob Layfield and Dr. Dan Scott. This collaboration allows us to leverage our expertise in RNA and neuron development and apply it to conditions like motor neuron disease.

Source: www.news-medical.net ↗
05From Spirulina to Seaweed: How are different types of algae integral to human diets?

Algae are photosynthetic aquatic creatures that grow through the consumption of nutrients, light, and carbon dioxide. They are a diverse group of creatures that include tiny single-celled algae and enormous kelp, as well as seaweed 1. Numerous prokaryotic and eukaryotic algae species are desirable food sources for humans due to their inherent qualities 2,3. Human intake of macroalgae such as seaweed and microalgae like phytoplankton dates back many years. Multicellular macroscopic aquatic plants, or macroalgae, are classified into three taxa: Phaeophyceae, or brown algae, Rhodophyta or red algae, and Chlorophyta or green algae. Microalgae, the unicellular counterpart of macroalgae, are categorized in a broader framework that includes prokaryotic cyanobacteria (blue-green algae), Euglenophyta, and Chlorophyta, which are genetically distinct from one another. The ancient populations of Chad and the Aztec culture were already familiar with the cyanobacteria spirulina, which is currently advertised as a superfood in the West 4. In Burma, Vietnam, and India, other cyanobacteria/microalgae, like Spirogyra and Oedogonium, were eaten as food or as a supplement 4. Seaweed is a staple of daily meals in many Asian and Pacific civilizations, including Korea, Japan, and Indonesia, as well as Hawaii and New Zealand 5.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →